Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statement of Stockholders' Equity

v3.23.1
Consolidated Statement of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Balance at beginning of period (in shares) at Dec. 31, 2021   76,778,000      
Balance at beginning of period at Dec. 31, 2021 $ 489,198 $ 8 $ 657,485 $ 2,125 $ (170,420)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Common stock issued pursuant to equity awards, net (in shares)   1,037,000      
Common stock issued pursuant to equity awards, net 13,835   13,835    
Repurchase of common stock (in shares)   (440,000)      
Repurchase of common stock (26,297)   (26,297)    
Stock-based compensation 18,599   18,599    
Other comprehensive income (loss) (1,075)     (1,075)  
Net income 33,586       33,586
Balance at end of period (in shares) at Mar. 31, 2022   77,375,000      
Balance at end of period at Mar. 31, 2022 $ 527,846 $ 8 663,622 1,050 (136,834)
Balance at beginning of period (in shares) at Dec. 31, 2022 78,745,000 78,745,000      
Balance at beginning of period at Dec. 31, 2022 $ 676,385 $ 8 722,778 (1,021) (45,380)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Common stock issued pursuant to equity awards, net (in shares)   1,236,000      
Common stock issued pursuant to equity awards, net $ 31,926   31,926    
Repurchase of common stock (in shares) 0        
Stock-based compensation $ 16,460   16,460    
Other comprehensive income (loss) (192)     (192)  
Net income $ 9,533       9,533
Balance at end of period (in shares) at Mar. 31, 2023 79,981,000 79,981,000      
Balance at end of period at Mar. 31, 2023 $ 734,112 $ 8 $ 771,164 $ (1,213) $ (35,847)